Europe's drug lottery: your zip code decides your treatment
In Europe, access to new therapies is not a medical question — it's a geographic one.
A patient in Romania waits more than three years for the same drug available to a patient in Berlin within two months. The European single market for medicines simply does not exist.
This image is used for illustrative purposes only.
At a Glance
The median wait time for a new drug in Europe is 532 days after regulatory approval; in Germany, that figure drops to 56 days — in Romania, it exceeds 1,200.
Public reimbursement coverage for innovative medicines has fallen from 42% to 28% across Europe between 2019 and 2025, meaning access is deteriorating even where the drugs exist.
A provisional deal on critical medicines was reached in May 2026, but it does not address national reimbursement delays — the core of the problem.
The continent’s two-tier pharmacy
Two months versus thirty-seven months. That is the documented gap — measured by the European Federation of Pharmaceutical Industries and Associations (EFPIA), the industry’s main lobbying and research body — between the shortest and longest patient wait times on the same continent, for the same molecules, approved by the same regulatory agency. This is not an anomaly. It is the ordinary structure of Europe’s pharmaceutical market.
EFPIA’s report, which tracked 168 innovative medicines authorized by the European Medicines Agency (EMA) between 2021 and 2024, puts the median delay at 532 days between market authorization and effective patient access. That single number conceals a deeply fractured reality. Germany, Europe’s benchmark market, clocks in at 56 days. Romania comes in at 1,201 — more than three years after the EU green light.
Between those two extremes, the geography of delay is consistent: Switzerland, Austria, and Denmark trail Germany at the top of the ranking, while Portugal, Lithuania, and Croatia cluster near the bottom alongside Romania.
More than a waiting game
The fracture runs deeper than wait times. It also shows up in the sheer number of drugs available in each country. Of the 168 medicines tracked, Germany lists 156 on its market. Malta lists 22. Austria offers 143, Italy 133, Spain 116. Latvia and Romania barely clear 25.
That shrinking catalog is compounded by a structural retreat from public reimbursement: in 2019, 42% of innovative medicines were fully covered by public health systems. By 2025, that figure had dropped to 28%. Nearly one in five available drugs is now accessible only under restrictive conditions. The double movement — fewer products, worse coverage — is no longer a question of national disparity. It is a trend.
Why the gap is so wide
The Germany-Romania chasm is less about market size than regulatory architecture. Berlin applies a framework — the Arzneimittelmarktneuordnungsgesetz (Germany’s drug market access law) — that allows immediate market entry the moment a drug receives European authorization, with price negotiations handled afterward. Most other European countries do the opposite: they condition real-world availability on the completion of a national evaluation and pricing process that can take anywhere from a few months to several years, depending on each system’s resources, methods, and political priorities.
The border between a German patient and a Romanian patient is not medical. It is administrative.
This structure explains why the EMA’s centralized authorization — designed to create a unified pharmaceutical space — has in practice produced regulatory uniformity without access uniformity.
A reform that targets shortages, not delays
In May 2026, the European Parliament and the Council of the EU reached a provisional agreement on a regulation targeting critical medicines — antibiotics, insulin, vaccines. The text, which grew out of a European Commission proposal from March 2025, aims to reshore pharmaceutical production capacity within Europe, coordinate national stockpiles, and embed resilience criteria into public procurement rules.
The deal responds to a genuine emergency: supply disruptions increased by 60% between 2018 and 2023, according to EMA data, and dependence on active pharmaceutical ingredients manufactured in Asia has been flagged as a strategic vulnerability since the COVID-19 pandemic. The European Parliament formalized that shift with its January 20, 2026 vote on the Critical Medicines Act.
But this framework does not touch the question of access delays for innovative therapies. That belongs to a different mechanism — national reimbursement procedures — over which Brussels has very limited leverage. The broader pharmaceutical legislation overhaul, expected in 2026–2027, attempts to address this by tying certain intellectual property protections to the speed and geographic breadth of market launches. The logic is to push drug companies to launch in more member states, faster. Whether that lever actually shifts industry behavior will depend on how companies recalibrate their launch strategies — and whether national agencies have the capacity to process applications quickly enough. The Commission controls neither variable directly.
Analysis — The phantom single market
The gap between Germany and Romania says something about more than their respective health systems. It exposes a structural contradiction at the heart of the European project: the EU built a common drug regulator but left each member state with full sovereignty over pricing and reimbursement. That sovereignty is fiercely defended — by Paris, by Berlin, by Warsaw — for reasons that differ but whose combined effect is the same: spontaneous convergence is impossible.
For a North American reader, the closest analogy would be a system in which the FDA approved a drug at the federal level, but each state then decided independently — on its own timeline, by its own criteria — whether to include it in its Medicaid program. Texas might act within two months. Louisiana might take four years. The federal approval would be real; the access would be theoretical.
Pharmaceutical innovation follows market responsiveness. When Germany offers access in 56 days and Romania in 1,201, the industry is not choosing between two markets of equal priority — it is sequencing its launch resources accordingly. Smaller markets with lengthy procedures end up at the back of the queue, sometimes after a product has already been reformulated or withdrawn elsewhere. This logic could suggest that the fragmentation of national markets functions, over time, as a permanent exclusion signal for less resourceful countries — not by design, but by economic rationality operating within a framework that provides no incentive to do otherwise.
The bottom line
The critical medicines deal solves the aspirin shortage problem. The access gap for innovative therapies remains unaddressed. The question Europe’s pharmaceutical framework has not yet answered is this: does the EU want a genuine single market for medicines — with real constraints on national procedures, at the cost of some erosion of health sovereignty — or does it accept that a patient’s postal code will permanently shape their odds of reaching the most recent treatments? That tension will define the next phase of European health policy. And it will be fought, as always, not in Brussels, but in the ministries of finance of twenty-seven member states.
Sources: Euronews · EFPIA · European Parliament · French National Health Insurance (L’Assurance Maladie)